Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis
Biomolecules · 2024
DOI: 10.3390/biom14101236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Stella Bähr und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Engineering Sciences, Heidelberg University, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Nitro Compounds, Drug Repositioning, Lymphangioleiomyomatosis, Thiazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health National Heart, Lung, And Blood Institute.
Abstract (Originalsprache)
Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease. Unfortunately, treatment with the mTORC1 inhibitor Rapamycin only slows disease progression, and incomplete responses are common. Thus, there remains an urgent need to identify new targets for the development of curative LAM treatments. Nitazoxanide (NTZ) is an orally bioavailable antiprotozoal small molecule drug approved for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in children and adults, with a demonstrated mTORC1 inhibitory effect in several human cell lines. NTZ’s excellent safety profile characterized by its more than 20 years of clinical use makes it a promising candidate for repurposing. Our rationale for this study was to further investigate NTZ’s effect using in vitro and in vivo LAM models and to elucidate the underlying molecular mechanism beyond mTORC1 inhibition. For this purpose, we investigated cell proliferation, cell viability, and changes in protein phosphorylation and expression in primary human cell cultures derived from LAM lung samples before translating our results into a syngeneic mouse model utilizing Tsc2-null cells. NTZ reduced cell growth for all tested cell lines at a dose of about 30 µM. Lower doses than that had no effect on cell viability, but doses above 45 µM lowered the viability by about 10 to 15% compared to control. Interestingly, our western blot revealed no inhibition of mTORC1 and only a mild effect on active ß-Catenin. Instead, NTZ had a pronounced effect on reducing pAkt. In the mouse model, prophylactic NTZ treatment via the intraperitoneal and oral routes had some effects on reducing lung lesions and improving body weight retention, but the results remain inconclusive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Engineering Sciences, Heidelberg University, 69120 Heidelberg, Germany.
- Biosputnik LLC., New York, NY 10002, USA.
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Emeritus Professor of Organic Chemistry and Biochemistry, University Hamburg, 20148 Hamburg, Germany.
ORCID-Profile: Stella Bähr, Ryan W Rue, Carly J Smith, Vera P Krymskaya
Förderung
- NHLBI NIH HHS
- National Institutes of Health National Heart, Lung, And Blood Institute
Zitieren
APA
Bähr, S., Rue, R. W., Smith, C. J., Evans, J. F., Köster, H., Krymskaya, V. P., & Pleimes, D. (2024). Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis. Biomolecules. https://doi.org/10.3390/biom14101236
Vancouver
Bähr S, Rue RW, Smith CJ, Evans JF, Köster H, Krymskaya VP, et al. Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis. Biomolecules. 2024. doi:10.3390/biom14101236
BibTeX
@article{Bhr2024,
author = {Bähr, Stella and Rue, Ryan W and Smith, Carly J and Evans, Jillian F and Köster, Hubert and Krymskaya, Vera P and Pleimes, Dirk},
title = {Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14101236}
}
EUVIMED